Keywords: Lundbeck, First-quarter 2012 financila results, Lexapro, Cipralex
Generic competition for Lexapro/Cipralex hits Lundbeck's first-quarter
Article | 02 May 2012
Danish drugmaker Lundbeck (LUND: DC) yesterday posted a 33% plunge in first-quarter 2012 net profit to 620 million Danish kroner ($110.5 million), missing the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
